A St. Louis federal court finds both of AstraZeneca’s patents protecting the beta blocker invalid due to double patenting and unenforceable because of AstraZeneca’s “inequitable conduct” with the patent office.

Preliminary results of the National Lipid Association statin safety task force's retrospective study of claims database shows Crestor's incidence of renal events and rhabdomyolysis fall in the middle of the statin class.

FDA Office of Drug Safety personnel will be publishing a paper on statins and rhabdomyolysis in an upcoming issue of the Journal of the American Medical Association, Associate Director for Science David Graham told the Senate Finance Committee during a Nov. 18 hearing on Merck's withdrawal of Vioxx